Predicting Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhages and Other Cerebrovascular Disorders in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Cerebral amyloid angiopathy (CAA) of amyloid β-protein (Aβ) type is common in Alzheimer's disease (AD). Aβ immunotherapies have been reported to induce CAA-related intracerebral hemorrhages (ICH) or vasogenic edema. For the purpose of developing a method to predict CAA-related ICH and other cerebrovascular disorders in AD, the biomarkers, and risk factors are reviewed. The biomarkers include (1) greater occipital uptake on amyloid positron emission tomography imaging and a decrease of cerebrospinal fluid Aβ40 levels as markers suggestive of CAA, and (2) symptomatic lobar ICH, lobar microhemorrhages, focal subarachnoidal hemorrhages/superficial siderosis, cortical microinfarcts, and subacute encephalopathy (caused by CAA-related inflammation or angiitis) as imaging findings of CAA-related ICH and other disorders. The risk factors include (1) old age and AD, (2) CAA-related gene mutations and apolipoprotein E genotype as genetic factors, (3) thrombolytic, anti-coagulation, and anti-platelet therapies, hypertension, and minor head trauma as hemorrhage-inducing factors, and (4) anti-amyloid therapies. Positive findings for one or more biomarkers plus one or more risk factors would be associated with a significant risk of CAA-related ICH and other cerebrovascular disorders. To establish a method to predict future occurrence of CAA-related ICH and other cerebrovascular disorders in AD, prospective studies with a large number of AD patients are necessary, which will allow us to statistically evaluate to what extent each biomarker or risk factor would increase the risk. In addition, further studies with progress of technologies are necessary to more precisely detect CAA and CAA-related cerebrovascular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Cordonnier, C., Al-Shahi Salman, R., & Wardlaw, J. (2007) · Brain · doi:10.1093/brain/awl387 · Cited by 703
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
Two Types of Sporadic Cerebral Amyloid Angiopathy
Thal, D. R., Ghebremedhin, E., Rüb, U., Yamaguchi, H., Del Tredici, K., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.282 · Cited by 446
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD
Yoshita, M., Fletcher, E., Harvey, D., Ortega, M., Martinez, O., Mungas, D. M., Reed, B. R., & DeCarli, C. S. (2006) · Neurology · doi:10.1212/01.wnl.0000249119.95747.1f · Cited by 434
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 1×
“…in hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D) with a point mutation at codon 693 of the Aβ precursor protein (APP) gene that causes a single amino acid substitution (Glu to Gln) at position 22 of Aβ, and the transgenic mouse model of this disease (Herzig et al., 2004).”
Cerebral amyloid angiopathy pathology and cognitive domains in older persons
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2011) · Annals of Neurology · doi:10.1002/ana.22112 · Cited by 383 · cited 1×
“It was reported that moderate-to-very severe CAA, but not mild-to-moderate CAA, is associated with lower performance in specific cognitive domains, most notably perceptual speed, separately from the effect of AD pathology (Arvanitakis et al., 2011).”
BackgroundScolding, N. J. (2005) · Brain · doi:10.1093/brain/awh379 · Cited by 372
Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
Gurol, M. E., Irizarry, M. C., Smith, E. E., Raju, S., Diaz-Arrastia, R., Bottiglieri, T., Rosand, J., Growdon, J. H., & Greenberg, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000191403.95453.6a · Cited by 339
Course of cerebral amyloid angiopathy–related inflammation
Kinnecom, C., Lev, M. H., Wendell, L., Smith, E. E., Rosand, J., Frosch, M. P., & Greenberg, S. M. (2007) · Neurology · doi:10.1212/01.wnl.0000260066.98681.2e · Cited by 333
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Brain microbleeds and Alzheimer’s disease: innocent observation or key player?
Cordonnier, C., & van der Flier, W. M. (2011) · Brain · doi:10.1093/brain/awq321 · Cited by 310
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study
Rosand, J., Hylek, E. M., O’Donnell, H. C., & Greenberg, S. M. (2000) · Neurology · doi:10.1212/wnl.55.7.947 · Cited by 305 · cited 2×
“Some hemorrhage-inducing factors are controllable or avoidable, including hypertension and use of thrombolytic/anticoagulation/anti-platelet therapies (Rosand et al., 2000; McCarron and Nicoll, 2004; Trouillas and von Kummer, 2006; Vernooij et al., 2009a; Arima et al., 2010).”
BackgroundPrevalence and severity of microbleeds in a memory clinic setting
Cordonnier, C., van der Flier, W. M., Sluimer, J. D., Leys, D., Barkhof, F., & Scheltens, P. (2006) · Neurology · doi:10.1212/01.wnl.0000210535.20297.ae · Cited by 305
Amyloid Angiopathy–Related Vascular Cognitive Impairment
Greenberg, S. M., Gurol, M. E., Rosand, J., & Smith, E. E. (2004) · Stroke · doi:10.1161/01.str.0000143224.36527.44 · Cited by 298
Cerebral Microinfarcts: A Systematic Review of Neuropathological Studies
Brundel, M., de Bresser, J., van Dillen, J. J., Kappelle, L. J., & Biessels, G. J. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.200 · Cited by 258
Goos, J. D. C., Kester, M. I., Barkhof, F., Klein, M., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2009) · Stroke · doi:10.1161/strokeaha.109.558197 · Cited by 213
Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy
Verbeek, M. M., Kremer, B. P. H., Rikkert, M. O., Van Domburg, P. H. M. F., Skehan, M. E., & Greenberg, S. M. (2009) · Annals of Neurology · doi:10.1002/ana.21694 · Cited by 202
11 C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage
Ly, J. V., Donnan, G. A., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G., Gong, S. J., Gunawan, R. M., Saunder, T., Ackerman, U., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cef7e3 · Cited by 157
Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice
Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133
Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease
Yates, P. A., Sirisriro, R., Villemagne, V. L., Farquharson, S., Masters, C. L., Rowe, C. C., & For the AIBL Research Group (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad36 · Cited by 130
Shinkai, Y., Yoshimura, M., Ito, Y., Odaka, A., Suzuki, N., Yanagisawa, K., & Ihara, Y. (1995) · Annals of Neurology · doi:10.1002/ana.410380312 · Cited by 127 · cited 1×
“In the process of vascular Aβ deposition, Aβ42 is initially deposited, and later Aβ40 is massively accumulated (Shinkai et al., 1995).”
BackgroundSuperficial siderosis in the general population
Vernooij, M. W., Ikram, M. A., Hofman, A., Krestin, G. P., Breteler, M. M. B., & van der Lugt, A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ae7c5e · Cited by 121
Thal, D. R., Papassotiropoulos, A., Saido, T. C., Griffin, W. S. T., Mrak, R. E., Kölsch, H., Tredici, K. D., Attems, J., & Ghebremedhin, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0707-9 · Cited by 103
(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00006-0 · Cited by 84
Self-citationWhat are the causes of pre-existing dementia in patients with intracerebral haemorrhages?
Cordonnier, C., Leys, D., Dumont, F., Deramecourt, V., Bordet, R., Pasquier, F., & Hénon, H. (2010) · Brain · doi:10.1093/brain/awq246 · Cited by 81
Cited by
Cerebral Amyloid Angiopathy: Emerging Concepts
Yamada, M. (2015) · Journal of Stroke · doi:10.5853/jos.2015.17.1.17 · Cited by 367
“The pathophysiology of Aβ-type CAA is shown in Figure 3.(18) CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infar…”
BackgroundSelf-citationDadar, M., Camicioli, R., Duchesne, S., Collins, D. L., & Initiative, F. T. A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12091 · Cited by 64
(2015) · Europe PMC (PubMed Central) · Cited by 37
Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Kamp, J. A., Moursel, L. G., Haan, J., Terwindt, G. M., Lesnik Oberstein, S. A. M. J., van Duinen, S. G., & van Roon-Mom, W. M. C. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0008 · Cited by 36
“CAA can also be found in at least 80% of Alzheimer’s disease (AD) patients (Yamada, 2012).”
BackgroundDaulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
Metadata
- Authors
- Yamada, M.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 64-64
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2108460969
- Cited by
- 38
- References
- 31
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.